Second-Line Fruquintinib Plus Paclitaxel Significantly Improves PFS But Not OS in Advanced Gastric or GEJ Adenocarcinoma

Fruquintinib/paclitaxel significantly improved PFS but not OS vs paclitaxel alone in the second-line treatment in patients with advanced gastric cancer.

Related Keywords

China ,Guangzhou ,Guangdong ,Junshi Biosciences ,Astellas Pharma ,Rui Hua Xu ,Merck Serono ,Sun Yat Sen University Cancer Center ,Bristol Myers Squibb ,Astrazeneca ,Phase 3 Frutiga Study Nct03223376 ,February 2024 Asco Plenary Series ,Patients With Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma ,Fruquintinib ,Fruzaqla ,